Clinical trial · Interventional
Effects of Flavor Modification for Management of Radiation Induced Dysgeusia
Effects of Flavor Modification for Management of Radiation Induced Dysgeusia in Head and Neck Cancer Patients
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Intervention for dysgeusia in head and neck cancer patients undergoing radiation therapy. This research proposal aims to investigate potential benefits of mBerry in improving quality of life and nutritional outcome in head and neck cancer patients' post-radiation therapy. Our hypothesis is that cancer patients undergoing radiation therapy will benefit from use of miracle berry in treatment of dysgeusia.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Dysgeusia | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| mBerry | Dietary Supplement | — | UNRESOLVED |
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Experimental group given mBerry tablet
- description
- For the experiment group, the clinician will be providing participant with daily 0.4 gram mBerry tablets (total of 112 tablets) to consume twice a day (for two meals) over an 8-week period. The participant will be provided with a log form to track mBerry use for the two meals each day for the 8-week period. They will be requested to bring log to each of the clinical visits which include bi-weekly taste assessments.
- interventionNames
- Dietary Supplement: mBerry
- type
- ACTIVE_COMPARATOR
- label
- Control group not receiving mBerry
- description
- The control group will not be given a placebo. The control group will come to clinic for bi-weekly taste assessments.
- interventionNames
- Other: No intervention
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Over 18 years * Diagnosis of mandibular cancer, tonsillar cancer, and lingual cancer * Receiving primary or adjuvant radiation therapy Exclusion Criteria: * Received a total glossectomy or total laryngectomy. * Patients with allergies to peanut, latex, peach, or soy will be excluded as they are at increased risk of allergy to mBerry. * Diagnosis of diabetes as well as prediabetic patients and those that are taking Metformin.
References
Publications (0)
Data not yet available